Skip NavigationSkip to Content
Return Return to Search Results

The NCI60 human tumour cell line anticancer drug screen

  1. Author:
    Shoemaker, R. H.

  2. Author Address

    NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diagnosis, Frederick, MD 21702 USA.;Shoemaker, RH, NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diagnosis, Frederick, MD 21702 USA.;shoemaker@dtpax2.ncifcrf.gov
    1. Year: 2006
    2. Date: Oct
  2. Journal: Nature Reviews Cancer
    1. 6
    2. 10
    3. Pages: 813-823
  4. Type of Article: Article
  5. ISSN: 1474-175X
  1. Abstract:

    The US National Cancer Institute (NCl) 60 human tumour cell line anticancer drug screen (NCl60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1038/nrc1951
  3. View record in Web of Science®
  4. WOS: 000241303000017

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel